

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 12/928,119
APPLICANTS : Guenzler-Pukall, et al.
FILING DATE : 2 December 2010
GROUP ART UNIT : 1627
EXAMINER : Samira J.M. Jean-Louis
DOCKET NO. : FP0600.4 CON
TITLE : STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA

M/S: ISSUE FEE
Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

AMENDMENT UNDER 37 CFR §1.312

This amendment is submitted in connection with the above-identified application. Applicants respectfully request consideration and entry of the following amendment to the subject application pursuant to 37 C.F.R. §1.312.

Amendments to the Claims are reflected in the listing of the claims, which begins on page 2 of this paper.

Remarks begin on page 3.

AMENDMENT
IN THE CLAIMS

Please amend claims 1, 3, 6, and 7 as indicated below.

1. (Presently amended) A method for treating a hypoxic or ischemic-related disorder or condition in a subject, the method comprising administering to the subject an effective amount of a heterocyclic carboxamide compound that stabilizes the alpha subunit of hypoxia inducible factor (HIF α).
2. (Previously amended) The method of claim 1, wherein the heterocyclic carboxamide compound inhibits HIF prolyl hydroxylase enzyme activity.
3. (Presently amended) The method of claim 1, wherein the hypoxic or ischemic-related disorder or condition is associated with an ischemic event.
4. (Original) The method of claim 3, wherein the ischemic event is acute.
5. (Original) The method of claim 3, wherein the ischemic event is associated with surgery, organ transplantation, infarction, trauma, or injury.
6. (Presently amended) The method of claim 1, wherein the ischemic-related disorder or condition is chronic.
7. (Presently amended) The method of claim 1, wherein the hypoxic or ischemic-related disorder or condition is associated with ischemic reperfusion injury in a subject.
8. (Original) The method of claim 1, wherein the administering is oral administration.
9. (Canceled)

REMARKS

Justification for the amendment is as follows:

The amendment to claims 1, 3, 6, and 7 removes the term “-related” from the claims. As amended, the claims recite “hypoxic and ischemic disorders and conditions” in place of “hypoxic and ischemic-related disorders and conditions.” The amendment is being made to further clarify the claimed subject matter.

The term “hypoxic and ischemic disorders and conditions” finds literal support throughout the specification, e.g., at paragraphs [0011], [0028], [0029], [0075], [0097], [0102], [0103], and [0105].

No new matter is added by any of these amendments, and entry is respectfully requested.

CONCLUSION


No new matter is believed to be introduced by this amendment, and its entry is respectfully requested.

The Commissioner is hereby authorized to charge the total of any fees due in this communication to Deposit Account No. 50-0811, referencing Docket No. FP0600.4 CON.

The Examiner is invited to call Applicant's representative at 415-978-1745 with any questions regarding the present communication or the above-identified application.

Respectfully submitted,

Date: 15 March 2012



Christopher Turner, Ph.D.
Reg. No. 45,167

FibroGen, Inc.
409 Illinois Street
San Francisco, CA 94158
Main: 415-978-1200
Direct: 415-978-1745
Facsimile: 415-978-1917
cturner@fibrogen.com